Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Development of a Standardized Reference Guide for Tuning Adherence to Dispense During a Initial Pharmaceutical Consulting (CP ) to the Patient With Multiple Myeloma Oral Chemotherapy Primocure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04045561
Recruitment Status : Completed
First Posted : August 5, 2019
Last Update Posted : August 5, 2019
Sponsor:
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Nīmes

Brief Summary:

The hypothesis is that the implementation of an initial Pharmaceutical Consultation (PC) program based on the provision of standardized information to patients treated for multiple myeloma as a first course of chemotherapy, could optimize their compliance with the delivered per os treatment.

The aim of this study is therefore to develop a standardised reference guide of information to be provided during prostate cancer in order to optimise the compliance of patients treated for multiple myeloma as a first course of chemotherapy per os.


Condition or disease
Multiple Myeloma

Layout table for study information
Study Type : Observational
Actual Enrollment : 10 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Elaboration of a Standardized Referential Guide of the Information to Optimize the Adherence to be Given During an Initial Pharmaceutical Consultation (CP) to the Patient Suffering From Multiple Myeloma in Primocure Chemotherapy Per os
Actual Study Start Date : June 1, 2015
Actual Primary Completion Date : December 31, 2016
Actual Study Completion Date : December 31, 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma




Primary Outcome Measures :
  1. evaluating the understanding [ Time Frame: Day 1 ]
    Questionnaire. quantitative variables: measurement of the mean and standard deviation or by their median and quartiles according to their distribution.

  2. evaluating understanding [ Time Frame: Day 1 ]
    Questionnaire. qualitative variables: measurement of their number and

  3. evaluating the quality of information [ Time Frame: Day 1 ]
    Questionnaire. quantitative variables: measurement of the mean and standard deviation or by their median and quartiles according to their distribution.

  4. evaluating quality of information [ Time Frame: Day 1 ]
    Questionnaire. qualitative variables: measurement of their number and percentage.


Secondary Outcome Measures :
  1. The time required for the pharmaceutical consultation [ Time Frame: Day 1 ]
    minutes

  2. satisfaction des patients [ Time Frame: Day 1 ]
    by an Analogue Visual Scale (0-10-very satisfied)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The patient is treated for multiple myeloma, is naive to any treatment and begins a chemotherapy protocol with oral therapy and whose course of care includes a stay in the Day Hospital or retrocessions.
Criteria

Inclusion criteria

  • The patient must be a member or beneficiary of a health insurance plan
  • The patient is at least 18 years old
  • The patient is treated for multiple myeloma, is naive to any treatment and begins a chemotherapy protocol with oral therapy and whose course of care includes a stay in the Day Hospital or retrocessions.

Criteria for non-inclusion

  • The subject is participating in another study
  • The subject is in an exclusion period determined by a previous study
  • The subject is under the protection of justice, guardianship or curatorship
  • It is impossible to give informed information about
  • The patient is pregnant, parturient, or breastfeeding
  • The patient receives a follow-up by a home nurse for the administration of oral medication
  • The patient is treated only with oral chemotherapy in the city
  • The patient has early dementia.

Translated with www.DeepL.com/Translator

-


Layout table for additonal information
Responsible Party: Centre Hospitalier Universitaire de Nīmes
ClinicalTrials.gov Identifier: NCT04045561     History of Changes
Other Study ID Numbers: LOCAL/2015/MF-01
First Posted: August 5, 2019    Key Record Dates
Last Update Posted: August 5, 2019
Last Verified: July 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases